{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T12:57:47Z","timestamp":1793969867656,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T00:00:00Z","timestamp":1554854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Nephrol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1186\/s12882-019-1314-1","type":"journal-article","created":{"date-parts":[[2019,4,10]],"date-time":"2019-04-10T05:18:22Z","timestamp":1554873502000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":116,"title":["Outcomes in patients with atypical hemolytic uremic syndrome treated with eculizumab in a long-term observational study"],"prefix":"10.1186","volume":"20","author":[{"given":"Jan","family":"Menne","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yahsou","family":"Delmas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fadi","family":"Fakhouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"Licht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c5sa","family":"Lommel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico E.","family":"Minetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Prov\u00f4t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Rondeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neil S.","family":"Sheerin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent E.","family":"Weekers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry A.","family":"Greenbaum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,4,10]]},"reference":[{"key":"1314_CR1","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0140-6736(17)30062-4","volume":"390","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Zuber J, Fremeaux-Bacchi V, Loirat C. Haemolytic uraemic syndrome. Lancet. 2017;390:681\u201396.","journal-title":"Lancet."},{"key":"1314_CR2","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.nefro.2015.07.005","volume":"35","author":"JM Campistol","year":"2015","unstructured":"Campistol JM, Arias M, Ariceta G, Blasco M, Espinosa L, Espinosa M, Grinyo JM, Macia M, Mendizabal S, Praga M, Roman E, Torra R, Valdes F, Vilalta R, Rodriguez de Cordoba S. An update for atypical haemolytic uraemic syndrome: diagnosis and treatment. A consensus document. Nefrologia. 2015;35:421\u201347.","journal-title":"Nefrologia."},{"key":"1314_CR3","doi-asserted-by":"publisher","first-page":"554","DOI":"10.2215\/CJN.04760512","volume":"8","author":"V Fremeaux-Bacchi","year":"2013","unstructured":"Fremeaux-Bacchi V, Fakhouri F, Garnier A, Bienaime F, Dragon-Durey MA, Ngo S, Moulin B, Servais A, Provot F, Rostaing L, Burtey S, Niaudet P, Deschenes G, Lebranchu Y, Zuber J, Loirat C. Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults. Clin J Am Soc Nephrol. 2013;8:554\u201362.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1314_CR4","volume-title":"Soliris (eculizumab) [prescribing information]","author":"US Food and Drug Administration","year":"2018","unstructured":"US Food and Drug Administration. Soliris (eculizumab) [prescribing information]. Boston, MA: Alexion Pharmaceuticals, Inc.; 2018."},{"key":"1314_CR5","volume-title":"Soliris (eculizumab) [summary of product characteristics]","author":"European Medicines Agency","year":"2017","unstructured":"European Medicines Agency. Soliris (eculizumab) [summary of product characteristics]. Paris: Alexion Europe SAS; 2017."},{"key":"1314_CR6","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1208981","volume":"368","author":"CM Legendre","year":"2013","unstructured":"Legendre CM, Licht C, Muus P, Greenbaum LA, Babu S, Bedrosian C, Bingham C, Cohen DJ, Delmas Y, Douglas K, Eitner F, Feldkamp T, Fouque D, Furman RR, Gaber O, Herthelius M, Hourmant M, Karpman D, Lebranchu Y, Mariat C, Menne J, Moulin B, Nurnberger J, Ogawa M, Remuzzi G, Richard T, Sberro-Soussan R, Severino B, Sheerin NS, Trivelli A, Zimmerhackl LB, Goodship T, Loirat C. Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome. N Engl J Med. 2013;368:2169\u201381.","journal-title":"N Engl J Med"},{"key":"1314_CR7","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1038\/ki.2014.423","volume":"87","author":"C Licht","year":"2015","unstructured":"Licht C, Greenbaum LA, Muus P, Babu S, Bedrosian CL, Cohen DJ, Delmas Y, Douglas K, Furman RR, Gaber OA, Goodship T, Herthelius M, Hourmant M, Legendre CM, Remuzzi G, Sheerin N, Trivelli A, Loirat C. Efficacy and safety of eculizumab in atypical hemolytic uremic syndrome from 2-year extensions of phase 2 studies. Kidney Int. 2015;87:1061\u201373.","journal-title":"Kidney Int"},{"issue":"3","key":"1314_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.kint.2015.11.026","volume":"89","author":"Larry A. Greenbaum","year":"2016","unstructured":"Greenbaum LA, Fila M, Ardissino G, Al-Akash SI, Evans J, Henning P, Lieberman KV, Maringhini S, Pape L, Rees L, van de Kar N, C.A.J., Vande Walle J, Ogawa M, Bedrosian CL, Licht C. Eculizumab is a safe and effective treatment in pediatric patients with atypical hemolytic uremic syndrome. Kidney Int 2016;89:701\u201311.","journal-title":"Kidney International"},{"key":"1314_CR9","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1053\/j.ajkd.2015.12.034","volume":"68","author":"F Fakhouri","year":"2016","unstructured":"Fakhouri F, Hourmant M, Campistol JM, Cataland SR, Espinosa M, Gaber AO, Menne J, Minetti EE, Provot F, Rondeau E, Ruggenenti P, Weekers LE, Ogawa M, Bedrosian CL, Legendre CM. Terminal complement inhibitor eculizumab in adult patients with atypical hemolytic uremic syndrome: a single-arm, open-label trial. Am J Kidney Dis. 2016;68:84\u201393.","journal-title":"Am J Kidney Dis"},{"issue":"suppl 1","key":"1314_CR10","first-page":"479","volume":"97","author":"R Vilalta","year":"2012","unstructured":"Vilalta R, Al-Akash S, Davin J, Diaz J, Gruppo R, Hernandez J, Jungraithmayr T, Langman C, Lapeyraque A, Macher M, Rodig N, Sherbotie J, Sherwinter J, Simonetti G, Smith J, Thornburg C, Wuhl E. Eculizumab therapy for pediatric patients with atypical hemolytic uremic syndrome: efficacy and safety outcomes of a retrospective study [abstract 1155]. Haematologica. 2012;97(suppl 1):479.","journal-title":"Haematologica."},{"key":"1314_CR11","doi-asserted-by":"crossref","unstructured":"Menne J, Delmas Y, Fakhouri F, Kincaid JF, Licht C, Minetti EE, Mix C, Provot F, Rondeau E, Sheerin NS, Wang J, Weekers LE, Greenbaum LA. Eculizumab prevents thrombotic microangiopathy in patients with atypical haemolytic uraemic syndrome in a long-term observational study. Clin Kidney J. 2018. [Epub ahead of print].","DOI":"10.1093\/ckj\/sfy035"},{"key":"1314_CR12","doi-asserted-by":"publisher","first-page":"1844","DOI":"10.2215\/CJN.02210310","volume":"5","author":"M Noris","year":"2010","unstructured":"Noris M, Caprioli J, Bresin E, Mossali C, Pianetti G, Gamba S, Daina E, Fenili C, Castelletti F, Sorosina A, Piras R, Donadelli R, Maranta R, van der Meer I, Conway EM, Zipfel PF, Goodship TH, Remuzzi G. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin J Am Soc Nephrol. 2010;5:1844\u201359.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1314_CR13","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1053\/j.ajkd.2015.04.010","volume":"66","author":"G Ardissino","year":"2015","unstructured":"Ardissino G, Possenti I, Tel F, Testa S, Salardi S, Ladisa V. Discontinuation of eculizumab treatment in atypical hemolytic uremic syndrome: an update. Am J Kidney Dis. 2015;66:172\u20133.","journal-title":"Am J Kidney Dis"},{"key":"1314_CR14","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1053\/j.ajkd.2014.01.434","volume":"64","author":"G Ardissino","year":"2014","unstructured":"Ardissino G, Testa S, Possenti I, Tel F, Paglialonga F, Salardi S, Tedeschi S, Belingheri M, Cugno M. Discontinuation of eculizumab maintenance treatment for atypical hemolytic uremic syndrome: a report of 10 cases. Am J Kidney Dis. 2014;64:633\u20137.","journal-title":"Am J Kidney Dis"},{"key":"1314_CR15","doi-asserted-by":"publisher","first-page":"50","DOI":"10.2215\/CJN.06440616","volume":"12","author":"F Fakhouri","year":"2017","unstructured":"Fakhouri F, Fila M, Provot F, Delmas Y, Barbet C, Chatelet V, Rafat C, Cailliez M, Hogan J, Servais A, Karras A, Makdassi R, Louillet F, Coindre JP, Rondeau E, Loirat C, Fremeaux-Bacchi V. Pathogenic variants in complement genes and risk of atypical hemolytic uremic syndrome relapse after eculizumab discontinuation. Clin J Am Soc Nephrol. 2017;12:50\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"4","key":"1314_CR16","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1093\/ndt\/gfx196","volume":"33","author":"Kioa L Wijnsma","year":"2017","unstructured":"Wijnsma KL, Duineveld C, Volokhina EB, van den Heuvel LP, van de Kar N, Wetzels JFM. Safety and effectiveness of restrictive eculizumab treatment in atypical haemolytic uremic syndrome. Nephrol Dial Transplant. 2018;33:635\u201345.","journal-title":"Nephrology Dialysis Transplantation"},{"key":"1314_CR17","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.kint.2016.10.005","volume":"91","author":"TH Goodship","year":"2017","unstructured":"Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Fremeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodriguez de Cordoba S, Roumenina LT, Sethi S, Smith RJ. Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a \"Kidney Disease: Improving Global Outcomes\" (KDIGO) Controversies Conference. Kidney Int. 2017;91:539\u201351.","journal-title":"Kidney Int"},{"key":"1314_CR18","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1111\/ajt.12077","volume":"13","author":"M Quintrec Le","year":"2013","unstructured":"Le Quintrec M, Zuber J, Moulin B, Kamar N, Jablonski M, Lionet A, Chatelet V, Mousson C, Mourad G, Bridoux F, Cassuto E, Loirat C, Rondeau E, Delahousse M, Fremeaux-Bacchi V. Complement genes strongly predict recurrence and graft outcome in adult renal transplant recipients with atypical hemolytic and uremic syndrome. Am J Transplant. 2013;13:663\u201375.","journal-title":"Am J Transplant"},{"key":"1314_CR19","doi-asserted-by":"publisher","first-page":"2924","DOI":"10.1097\/TP.0000000000001909","volume":"101","author":"C Levi","year":"2017","unstructured":"Levi C, Fremeaux-Bacchi V, Zuber J, Rabant M, Devriese M, Snanoudj R, Scemla A, Amrouche L, Mejean A, Legendre C, Sberro-Soussan R. Midterm outcomes of 12 renal transplant recipients treated with eculizumab to prevent atypical hemolytic syndrome recurrence. Transplantation. 2017;101:2924\u201330.","journal-title":"Transplantation."},{"key":"1314_CR20","doi-asserted-by":"publisher","first-page":"770","DOI":"10.1053\/j.ajkd.2017.06.024","volume":"70","author":"C Duineveld","year":"2017","unstructured":"Duineveld C, Verhave JC, Berger SP, van de Kar N, Wetzels JFM. Living donor kidney transplantation in atypical hemolytic uremic syndrome: a case series. Am J Kidney Dis. 2017;70:770\u20137.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"1314_CR21","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/j.ekir.2018.11.010","volume":"4","author":"Andrew M. Siedlecki","year":"2019","unstructured":"Siedlecki AM, Isbel N, Vande Walle J, James Eggleston J, Cohen DJ. Eculizumab use for kidney transplantation in patients with a diagnosis of atypical hemolytic uremic syndrome. Kidney Int Rep. 2018;4(3):434\u201346.","journal-title":"Kidney International Reports"},{"key":"1314_CR22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/s40620-016-0288-3","volume":"30","author":"J Vande Walle","year":"2017","unstructured":"Vande Walle J, Delmas Y, Ardissino G, Wang J, Kincaid JF, Haller H. Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment. J Nephrol. 2017;30:127\u201334.","journal-title":"J Nephrol"},{"key":"1314_CR23","doi-asserted-by":"crossref","unstructured":"Socie G, Caby-Tosi MP, Marantz JL, Cole JA, Bedrosian CL, Gasteyger C, Mujeebuddin A, Hillmen P, Vande Walle J, Haller H. Eculizumab in paroxysmal nocturnal haemoglobinuria and atypical haemolytic uraemic syndrome: 10-year pharmacovigilance analysis. Br J Haematol. 2019. [Epub ahead of print].","DOI":"10.1111\/bjh.15790"},{"key":"1314_CR24","doi-asserted-by":"publisher","first-page":"734","DOI":"10.15585\/mmwr.mm6627e1","volume":"66","author":"LA McNamara","year":"2017","unstructured":"McNamara LA, Topaz N, Wang X, Hariri S, Fox L, MacNeil JR. High risk for invasive meningococcal disease among patients receiving eculizumab (soliris) despite receipt of meningococcal vaccine. MMWR Morb Mortal Wkly Rep. 2017;66:734\u20137.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"1314_CR25","first-page":"44","volume":"29","author":"G Ariceta","year":"2018","unstructured":"Ariceta G, Ardissino G, Sartz L, Fakhouri F, Gasteyger C, Al-Dakkak I. Thrombotic microangiopathy frequency in patients with atypical HUS: discontinuing vs remaining on eculizumab treatment [abstract FR-OR017]. J Am Soc Nephrol. 2018;29:44.","journal-title":"J Am Soc Nephrol"}],"container-title":["BMC Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12882-019-1314-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12882-019-1314-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T19:08:29Z","timestamp":1586372909000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcnephrol.biomedcentral.com\/articles\/10.1186\/s12882-019-1314-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,10]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1186\/s12882-019-1314-1","relation":{},"ISSN":["1471-2369"],"issn-type":[{"value":"1471-2369","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,10]]},"assertion":[{"value":"19 December 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 March 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All patients and\/or parents\/guardians provided written informed consent before entry into the current study. Ethics approvals have been obtained by institutional review boards or ethics committees in participating institutions as follows:Australia: Alice Springs Hospital, Central Australian HERC, Alice Springs; Royal Adelaide Hospital, SAH HREC \/ CALHN (CEC), Royal Adelaide HREC (LEC), Adelaide; Austria: Medizinische Universitaet Innsbruck, Ethikkommission der Medizinischen Unitversit\u00e4t Innsbruck, Innsbruck; Medical University Graz Division of Pediatric Nephrology, Ethikkommission der Medizinischen Unitversit\u00e4t Innsbruck, Graz; Belgium: CHU de Li\u00e8ge, Comit\u00e9 d\u2019Ethique Hospitalo-Facuitarire Universitaire de Li\u00e8ge (707) (CEC), Liege; UZ Gent Dienst Nefrologie, Comit\u00e9 d\u2019Ethique Hospitalo-Facuitarire Universitaire de Li\u00e8ge (707) (CEC) UZ Gent Ethisch Comit\u00e9 (LEC), Gent; Canada: Centre Hospitalier Universitaire (CHU) Sainte-Justine, Comit\u00e9 d\u2019\u00e9thique de la Recherche CHU Sainte-Justine (LEC), Montreal; The Hospital for Sick Children, The Hospital for Sick Children REB, Toronto; University Health Network, University Health Network REB, Toronto; France: H\u00f4pital Pasteur \u2013 CHU de Nice Pole Urologie \u2013 N\u00e9phrologie, CNOM, CNIL, CCTIRS, Nice; CHU de Bordeaux Pellegrin, CNOM, CNIL, CCTIRS, Bordeaux; H\u00f4pital Robert Debr\u00e9, Service de N\u00e9phrologie P\u00e9diatrique, CNOM, CNIL, CCTIRS, Paris; Le Kremlin Bicetre Hospital, Nephrology Unit, CNOM, CNIL, CCTIRS, Le Kremlin Bicetre; H\u00f4pital Edouard Herriot, CNOM, CNIL, CCTIRS, Lyon; CHU de Nantes-H\u00f4pital, Hotel Dieu - Nephro-Greffe (Nephrology), CNOM, CNIL, CCTIRS, Nantes; CHU de Caen Service de N\u00e9phrologie H\u00f4pital Cl\u00e9menceau, CNOM, CNIL, CCTIRS, Caen; H\u00f4pital Bretonneau, IRC Transplantation R\u00e9nale, CNOM, CNIL, CCTIRS, Tours; H\u00f4pital de Bois Guillaume-CHU de Rouen, CNOM, CNIL, CCTIRS, Rouen Cedex; CHU St. Etienne\u2013H\u00f4pital Nord, CNOM, CNIL, CCTIRS, Saint Priest En Jarez; Nouvel H\u00f4pital Civil, CNOM, CNIL, CCTIRS, Strasbourg; CHRU de Lille-H\u00f4pital A. Calmette (Nephrologie), CNOM, CNIL, CCTIRS, Lille; H\u00f4pital Tenon, CNOM, CNIL, CCTIRS, Paris; Centre Hospitalier Inter-Communal de Cornouaille, CNOM, CNIL, CCTIRS, Quimper; H\u00f4pital de la Timone Enfants, Unit\u00e9 de N\u00e9phrologie, Service de P\u00e9diatrie Multidisciplinaire, CNOM, CNIL, CCTIRS, Marseille; CHU-CH Charles Nicolle Pavillon de P\u00e9diatrie, CNOM, CNIL, CCTIRS, Rouen; Service de N\u00e9phrologie\/H\u00e9modialyse, CHR Orl\u00e9ans, CNOM, CNIL, CCTIRS, Orleans; Germany: Medizinische Klinik II - Nephrologie und Klinische Immunologie, Ethik-Kommission an der Medizinischen Fakult\u00e4t (LEC), Aachen; Hannover University Clinic Adult Nephrology, Medizinische Hochschule Hannover Ethikkomission Vorsitzender (LEC), Hannover; Hannover University Clinic Pediatric Nephrology Medizinische Hochschule Hannover Ethikkomission Vorsitzender (LEC). Hannover; Universitaet Heidelberg, Ethik-Kommission der Medizinischen Fakult\u00e4t Heidelberg (LEC), Heidelberg; Italy: Fondazione IRCCS Ca Granda, Ospedale Maggiore Policlinico, The IRCCS (Italian Research Hospital) Ca' Granda Foundation, Ospedale Maggiore General Hospital (LEC), Milano; Azienda Ospedaliero-Universitaria Careggi, Comitato Etico dell\u2019Azienda Ospedaliero-Universitaria Careggi (LEC), Firenze; A.O. Papa Giovanni XXIII, Comitato di Bioetica Azienda Ospedali Riuniti di Bergamo (CEC), Bergamo; Istituto Giannina Gaslini, Istituto Giannina Gaslini Ethics Committee for Scientific Biomedical Research (LEC), Genova; Ospedale dei Bambini G. di Cristina, Arnas Civico di Cristina Benfratelli Comitato di Bioetica (LEC), Palermo; Netherlands: Academic Center Amsterdam (AMC), Dept. Nephrology \/ Dept. Pediatric Nephrology Stichting CGR (CEC), Amsterdam; University Medical Center Nijmegen (UMCN), St. Radboud Dept. Nephrology \/ Dept. Pediatrics, Stichting CGR (CEC), Nijmegen; Radboud University Medical Center, Stichting CGR (CEC), Nijmegen; Sweden: Karolinska Institutet, Karolinska University Hospital \u2013 Huddinge, Regionala Etikpr\u00f6vningsn\u00e4mnden i Stockholm, Stockholm; Switzerland: INSELSPITAL Universitaetsklinik fuer Kinderheilkunde, Kindernephrologie, Kantonale Ethikkommission Bern (KEK) (LEC), Bern; United Kingdom: Exeter Kidney Unit, Royal Devon and Exeter Hospital (Wonford), NRES Committee South West - Cornwall & Plymouth (CEC), Royal Devon & Exeter NHS Foundation Trust (R&D), Exeter; Great Ormond Street Hospital NRES Committee South West - Cornwall & Plymouth (CEC), UCL Institute of Child Health \/ Great Ormond Street Hospital for Children NHS Foundation Trust (R&D) London; Newcastle Upon Tyne Hospitals NHS Foundation Trust, NRES Committee South West - Cornwall & Plymouth (CEC), Newcastle upon Tyne Hospital NHS Foundation Trust (R&D), Newcastle upon Tyne; Clinical Apheresis Unit, Level 1, Beatson WoSCC Gartnavel General Hospital, NRES Committee South West - Cornwall & Plymouth (CEC), Greater Glasgow & Clyde Health Board (R&D), Glasgow; City Hospital, Nottingham University Hospitals NHS Trust, NRES Committee South West - Cornwall & Plymouth (CEC), Nottingham University Hospitals NHS Trust (R&D), Nottingham; United States: Driscoll Children\u2019s Kidney Center, Driscoll Children\u2019s Hospital IRB, Corpus Christi, TX; Fort Wayne Medical Oncology and Hematology, WIRB (Western IRB - central IRB), Fort Wayne, IN; Arthur James Cancer Hospital, WIRB (Western IRB - central IRB), Columbus, OH; Weill Cornell Medical College, Weill Cornell Medical College IRB, New York, NY; Fox Valley Hematology, Affinity IRB, Oshkosh, WI; Emory Healthcare-Children\u2019s Center, Emory IRB, Atlanta, GA; Cincinnati Children\u2019s Hospital, CCHMC IRB, Cincinnati, OH; Providence Sacred Heart Medical Center & Children\u2019s Hospital, IRB Spokane, Spokane, WA; Children\u2019s Memorial Hospital, Ann & Robert H. Lurie Children\u2019s Hospital of Chicago IRB, Chicago, IL; Westchester Oncology \/ Hematology Group (New York Medical College Committee for Protection of Human Subjects), Hawthorne, NY; Methodist Hospital (TMHRI IRB), Houston, TX; Children\u2019s Hospital Boston, Boston Children\u2019s Hospital IRB, Boston, MA; University of Utah School of Medicine Pediatric Pharmacology Program, University of Utah IRB, Salt Lake City, UT; Dunwoody Pediatrics & Children\u2019s Healthcare of Atlanta, WIRB (Western IRB - central IRB), Dunwoody and Atlanta, GA; Seattle Children\u2019s Hospital, Seattle Children\u2019s Hospital IRB, Seattle, WA; Children\u2019s Hospital at Montefiore, Albert Einstein College of Medicine IRB, Bronx, NY; Henry Ford Health System, Henry Ford Health System IRB, Detroit, MI; Vanderbilt University Medical Center, Vanderbilt University IRB, Nashville, TN; Duke University Medical Center, Duke University Health System IRB, Durham, NC. Written informed consent was obtained from all participants.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JM has received lecture and\/or advisory fees from Alexion Pharmaceuticals, Inc., AstraZeneca, Berlin-Chemie, Daiichi Sankyo, Boehringer Ingelheim, and Novartis. YD has received fees from Alexion Pharmaceuticals, Inc., for participation in a symposium and from Sanofi-Ablynx for participation in advisory boards. FF has received fees for participation in advisory boards, experts\u2019 meetings, and\/or teaching courses from Alexion Pharmaceuticals, Inc. CL has received grant\/research support and\/or consultancy fees from Achillion Pharmaceuticals, Inc., Alexion Pharmaceuticals, Inc., and CSL Behring; has received honoraria from Alexion Pharmaceuticals, Inc. and CSL Behring; has submitted patents for CSL Behring and Finnegan, Henderson, Farabow, Garrett & Dunner; is a member of the Editorial Boards for Kidney International, Nephrology Dialysis Transplantation, and Pediatric Nephrology; is a Steering Committee Member of the Alport Syndrome Treatments and Outcomes Registry (ASTOR) and Member of the Safety Board of the European Treatment Trial for Alport Syndrome (EARLY PRO-TECT); is the aHUS International Registry Scientific Advisory Board Chair and HUS International Chair for Alexion Pharmaceuticals, Inc.; and has participated in the Eculizumab in Adolescent Patients With Plasma Therapy-Resistant aHUS (C08\u2013002; NCT00844844), Eculizumab in Adolescent Patients With Plasma Therapy-Sensitive aHUS (C08\u2013003; NCT00844428), and Eculizumab in Pediatric Patients With Atypical Hemolytic-Uremic Syndrome (C10\u2013003; NCT01193348) clinical studies for Alexion Pharmaceuticals, Inc. \u00c5L is an employee and stockholder of Alexion Pharma GmbH, Zurich, Switzerland. EEM has participated in the C10\u2013004 adult interventional study (NCT01194973) and in the C11\u2013003 observational, follow-up study (NCT01522170) of atypical hemolytic uremic syndrome patients for Alexion Pharmaceuticals, Inc. FP has received honoraria from Alexion Pharmaceuticals, Inc. ER has received fees for participation in advisory boards, experts\u2019 meetings, and\/or teaching courses from Alexion Pharmaceuticals, Inc. NSS has received research funding from GlaxoSmithKline plc. JW is an employee and stockholder of Alexion Pharmaceuticals, Inc. LEW has received fees for participation in advisory boards from Alexion Pharmaceuticals, Inc. LAG has received research funding for Emory University from Alexion Pharmaceuticals, Inc., for his participation in the Eculizumab in Pediatric Patients and aHUS International Registry clinical studies; has received grant\/research support and\/or consultancy fees from AbbVie Inc., Alexion Pharmaceuticals, Inc., Bristol-Myers Squibb, Advicenne Pharmaceuticals, Mallinckrodt Pharmaceuticals, Otsuka America Pharmaceutical, Inc., and Vifor Pharma; has served as a member of a scientific advisory board for Alexion Pharmaceuticals, Inc., and as a member of data safety monitoring boards for Retrophin, Inc. and Relypsa Pharmaceuticals.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"125"}}